SHPH01
MISSION® LentiPlex® Human Pooled shRNA Library
For Rapid, Convenient Genome-wide shRNA Screens
Sinónimos:
Human shRNA Library, LentiPlex shRNA Library
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
| Tamaño de envase | SKU | Disponibilidad | Precio |
|---|---|---|---|
| 1 set | Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad | 9530,00 € |
Acerca de este artículo
NACRES:
NA.51
UNSPSC Code:
41105904
Concentration:
≥5x108 VP/ml (via p24 assay)
Technique(s):
capture ELISA: 5 × 108 TU/mL using p24
9530,00 €
Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
product line
MISSION®
concentration
≥5x108 VP/ml (via p24 assay)
technique(s)
capture ELISA: 5 × 108 TU/mL using p24
shipped in
dry ice
storage temp.
−70°C
General description
MISSION LentiPlex Pooled Libraries bring the power of the MISSION TRC shRNA collection together with Sigma¢s lentiviral manufacturing expertise to enable genome-wide RNAi screens at your bench-top. The LentiPlex pooled system provides enhanced delivery and long-term gene silencing in non-dividing and primary cell lines allowing unlimited discovery potential. The convenient format now makes rapid whole-genome RNAi screens accessible to any researcher with minimal reagent, time or capital equipment investment.
The MISSION LentiPlex Human shRNA Pooled Library is a genome-wide lentiviral pool produced using a proprietary process. The library consists of over 75,000 shRNA constructs from the TRC collection targeting 15,000+ human genes. Each library is tested for shRNA representation before product release to ensure robust library coverage. The library is provided in ready-to-use lentiviral format at titers of at least 5 x 108 TU/ml via p24 assay and is pre-divided into ten subpools of approximately 8,000 shRNA constructs each. Amplification and sequencing primers are also provided for downstream target identification.
The library is pre-divided into ten subpools of approximately 8,000 shRNA constructs each. Each library is enough material for six screens at 100X representation.
Please visit sigma.com/lentiplex to learn more and see example data and uses.
The MISSION LentiPlex Human shRNA Pooled Library is a genome-wide lentiviral pool produced using a proprietary process. The library consists of over 75,000 shRNA constructs from the TRC collection targeting 15,000+ human genes. Each library is tested for shRNA representation before product release to ensure robust library coverage. The library is provided in ready-to-use lentiviral format at titers of at least 5 x 108 TU/ml via p24 assay and is pre-divided into ten subpools of approximately 8,000 shRNA constructs each. Amplification and sequencing primers are also provided for downstream target identification.
The library is pre-divided into ten subpools of approximately 8,000 shRNA constructs each. Each library is enough material for six screens at 100X representation.
Please visit sigma.com/lentiplex to learn more and see example data and uses.
Application
MISSION® LentiPlex® Human Pooled shRNA Library has been used to transfect human colon adenocarcinoma cell line HT29 for shRNA screening and bioinformatics analysis.[1]
Other Notes
Deconvolution of shRNA Pools
Sigma′s deconvolution service lets you easily identify the genes that impact your pooled shRNA screen.
Contact your local Sigma sales representative for more information or submit an inquiry to MISSION RNAi
Sigma′s deconvolution service lets you easily identify the genes that impact your pooled shRNA screen.
- Next-generation sequencing of clonesgives a precise number of individual clone occurrence within a pooled shRNA sample
- Comprehensive, reproducible results from pooled shRNA screens
- Statistically robust and information-rich data
Contact your local Sigma sales representative for more information or submit an inquiry to MISSION RNAi
Legal Information
LentiPlex is a registered trademark of Merck KGaA, Darmstadt, Germany
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
1 of 1
Este artículo | |||
|---|---|---|---|
| concentration ≥5x108 VP/ml (via p24 assay) | concentration ≥5x108 VP/ml (via p24 assay) | concentration ≥5x108 VP/ml (via p24 assay) | concentration ≥5x108 VP/ml (via p24 assay) |
| product line MISSION® | product line MISSION® | product line MISSION® | product line MISSION® |
| technique(s) capture ELISA: 5 × 108 TU/mL using p24 | technique(s) capture ELISA: 5 x 108 TU/mL using p24 | technique(s) capture ELISA: 5 x 108 TU/mL using p24 | technique(s) capture ELISA: 5 x 108 TU/mL using p24 |
| storage temp. −70°C | storage temp. −70°C | storage temp. −70°C | storage temp. −70°C |
| shipped in dry ice | shipped in dry ice | shipped in dry ice | shipped in dry ice |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 200 |
Clase de almacenamiento
12 - Non Combustible Liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Artículos
Presenting an article on Pooled Lentiviral shRNA Screens to Identify Essential Cancer Pathways
RNAi Consortium (TRC): Collaborative effort among academic labs and biotech/pharma institutes advancing RNA interference research.
Rong Geng et al.
Chinese journal of cancer, 36(1), 63-63 (2017-08-02)
The mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor trametinib has shown promising therapeutic effects on melanoma, but its efficacy on colorectal cancer (CRC) is limited. Synthetic lethality arises with a combination of two or more separate gene mutations that causes
Davide Zecchin et al.
EMBO molecular medicine, 12(8), e11987-e11987 (2020-07-17)
Triple-negative breast cancer (TNBC) has poorer prognosis compared to other types of breast cancers due to the lack of effective therapies and markers for patient stratification. Loss of PTEN tumor suppressor gene expression is a frequent event in TNBC, resulting
Xue-Cen Wang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(14), 4567-4579 (2019-04-14)
Neoadjuvant chemoradiotherapy (neoCRT) is a standard treatment for locally advanced rectal cancer (LARC); however, resistance to chemoradiotherapy is one of the main obstacles to improving treatment outcomes. The goal of this study was to identify factors involved in the radioresistance
Número de artículo de comercio global
| SKU | GTIN |
|---|---|
| SHPH01-1SET | 04061826600740 |